1
|
Li R, Chen WC, Pang XQ, et al: Combined
effect of sCD40L and PI3K siRNA on transplanted tumours growth and
microenvironment in nude mice with gastric cancer. Mol Biol Rep.
39:8755–8761. 2012. View Article : Google Scholar : PubMed/NCBI
|
2
|
Pietrantonio F, De Braud F, Da Prat V, et
al: A review on biomarkers for prediction of treatment outcome in
gastric cancer. Anticancer Res. 33:1257–1266. 2013.PubMed/NCBI
|
3
|
Braun S, Kentenich C, Janni W, et al: Lack
of effect of adjuvant chemotherapy on the elimination of single
dormant tumor cells in bone marrow of high-risk breast cancer
patients. J Clin Oncol. 18:80–86. 2000.PubMed/NCBI
|
4
|
Aogi K, Rai Y, Ito Y, et al: Efficacy and
safety of ixabepilone in taxane-resistant patients with metastatic
breast cancer previously treated with anthracyclines: results of a
phase II study in Japan. Cancer Chemother Pharmacol. 71:1427–1433.
2013. View Article : Google Scholar : PubMed/NCBI
|
5
|
Harland S, Staffurth J, Molina A, et al:
Effect of abiraterone acetate treatment on the quality of life of
patients with metastatic castration-resistant prostate cancer after
failure of docetaxel chemotherapy. Eur J Cancer. 49:3648–3657.
2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Sawai K, Goi T, Koneri K, et al: Partial
response after transcatheter arterial infusion chemotherapy in a
patient with systemic chemotherapy-resistant unresectable colon
cancer and hepatic metastasis: (case report). World J Surg Oncol.
11:2032013. View Article : Google Scholar : PubMed/NCBI
|
7
|
Oyamada Y, Maeshima A, Takeuchi K and Kato
R: A case of lung cancer resistant to pemetrexed responding to S-1
monotherapy. Gan To Kagaku Ryoho. 40:781–784. 2013.(In Japanese).
PubMed/NCBI
|
8
|
Neuzillet C, Hentic O, Rousseau B, et al:
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant
to gemcitabine and platinum-salts. World J Gastroenterol.
18:4533–4541. 2012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Galmarini CM, Mackey JR and Dumontet C:
Nucleoside analogues and nucleobases in cancer treatment. Lancet
Oncol. 3:415–424. 2002. View Article : Google Scholar : PubMed/NCBI
|
10
|
Löwenberg B: Sense and nonsense of
high-dose cytarabine for acute myeloid leukemia. Blood. 121:26–28.
2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Fan X, Wu W, Shi H and Han J: RNA
interference targeting CD147 inhibits the invasion of human
cervical squamous carcinoma cells by downregulating MMP-9. Cell
Biol Int. 37:737–741. 2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
Zhao S, Ma W, Zhang M, et al: High
expression of CD147 and MMP-9 is correlated with poor prognosis of
triple-negative breast cancer (TNBC) patients. Med Oncol.
30:3352013. View Article : Google Scholar
|
13
|
Piao S, Zhao S, Guo F, et al: Increased
expression of CD147 and MMP-9 is correlated with poor prognosis of
salivary duct carcinoma. J Cancer Res Clin Oncol. 138:627–635.
2012. View Article : Google Scholar : PubMed/NCBI
|
14
|
Kim JY, Kim WJ, Kim H, et al: The
stimulation of CD147 induces MMP-9 expression through ERK and
NF-kappaB in macrophages: implication for atherosclerosis. Immune
Netw. 9:90–97. 2009. View Article : Google Scholar
|
15
|
Farabegoli F, Papi A and Orlandi M:
(−)-Epigallocatechin-3-gallate down-regulates EGFR, MMP-2, MMP-9
and EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant
cells. Biosci Rep. 31:99–108. 2011. View Article : Google Scholar
|
16
|
Chow S, Patel H and Hedley DW: Measurement
of MAP kinase activation by flow cytometry using phospho-specific
antibodies to MEK and ERK: potential for pharmacodynamic monitoring
of signal transduction inhibitors. Cytometry. 46:72–78. 2001.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Fukazawa H, Noguchi K, Murakami Y and
Uehara Y: Mitogen-activated protein/extracellular signal-regulated
kinase kinase (MEK) inhibitors restore anoikis sensitivity in human
breast cancer cell lines with a constitutively activated
extracellular-regulated kinase (ERK) pathway. Mol Cancer Ther.
1:303–309. 2002.PubMed/NCBI
|
18
|
Sunayama J, Matsuda K, Sato A, et al:
Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in
the maintenance of self-renewal and tumorigenicity of glioblastoma
stem-like cells. Stem Cells. 28:1930–1939. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
Hao JL, Cozzi PJ, Khatri A, et al:
CD147/EMMPRIN and CD44 are potential therapeutic targets for
metastatic prostate cancer. Curr Cancer Drug Targets. 10:287–306.
2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Kanekura T and Chen X: CD147/basigin
promotes progression of malignant melanoma and other cancers. J
Dermatol Sci. 57:149–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Nabeshima K, Iwasaki H, Koga K, et al:
Emmprin (basigin/ CD147): matrix metalloproteinase modulator and
multifunctional cell recognition molecule that plays a critical
role in cancer progression. Pathol Int. 56:359–367. 2006.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Boulos S, Meloni BP, Arthur PG, et al:
Evidence that intracellular cyclophilin A and cyclophilin A/CD147
receptor-mediated ERK1/2 signalling can protect neurons against in
vitro oxidative and ischemic injury. Neurobiol Dis. 25:54–64. 2007.
View Article : Google Scholar
|
23
|
Kim K, Kim H, Jeong K, et al: Release of
overexpressed CypB activates ERK signaling through CD147 binding
for hepatoma cell resistance to oxidative stress. Apoptosis.
17:784–796. 2012. View Article : Google Scholar : PubMed/NCBI
|